{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ZIVO","limit":50},"count":50,"signals":[{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":27,"context":"ratify the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2025; | | | | | | | 3. | To approve (on an advisory basis) the compensation of our named executive officers; and | | | | | | | 4. | To transact any other business that may properly be brought before the Annual Meeting or any adjournment or postponement thereof. | | The Board of Directors recommends a vote","filed_date":"2025-04-25","accession":"0001654954-25-004654","full_text":"https://origin.rootz.global/static/filing/0001654954-25-004654.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":27,"context":"s, or it could impact our ability to successfully commercialize our current product candidates. **Because our ZIVO algae is currently produced by only one grower, the loss of this grower would have a material adverse impact on our operating results and cash flows.** Currently, only one facility grows our ZIVO algae. Any termination of a business relationship with, or a significant sustained reduction in business receive","filed_date":"2025-03-18","accession":"0001654954-25-002948","full_text":"https://origin.rootz.global/static/filing/0001654954-25-002948.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":27,"context":"ify the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2024; and | | | | | | | 3. | To approve (on an advisory basis) the compensation of our named executive officers. | | The Board of Directors has fixed the close of business on Friday, April 12, 2024 as the record date for determination of the shareholders entitled to notice of and to vote at the Annual Meeting","filed_date":"2024-04-26","accession":"0001654954-24-005060","full_text":"https://origin.rootz.global/static/filing/0001654954-24-005060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":27,"context":", or it could impact our ability to successfully commercialize our current product candidates. ***Because our ZIVO algae is currently produced by only one grower, the loss of this grower would have a material adverse impact on our operating results and cash flows.*** Currently, only one facility grows our ZIVO algae. Any termination of a business relationship with, or a significant sustained reduction in business receiv","filed_date":"2024-03-15","accession":"0001654954-24-003228","full_text":"https://origin.rootz.global/static/filing/0001654954-24-003228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ed compliance with the applicable Nasdaq requirements, there can be no assurances regarding the continued listing of our securities on Nasdaq. The delisting of our securities from Nasdaq would have a material adverse effect on our access to capital markets and any limitation on market liquidity or reduction in the price of our Common Stock as a result of that delisting would adversely affect our ability to raise capital","filed_date":"2023-11-03","accession":"0001654954-23-013753","full_text":"https://origin.rootz.global/static/filing/0001654954-23-013753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ed compliance with the applicable Nasdaq requirements, there can be no assurances regarding the continued listing of our securities on Nasdaq. The delisting of our securities from Nasdaq would have a material adverse effect on our access to capital markets and any limitation on market liquidity or reduction in the price of our Common Stock as a result of that delisting would adversely affect our ability to raise capital","filed_date":"2023-10-04","accession":"0001654954-23-012588","full_text":"https://origin.rootz.global/static/filing/0001654954-23-012588.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"ify the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2023; and | | | | | | | 3. | To approve (on an advisory basis) the compensation of our named executive officers. | | The Board of Directors has fixed the close of business on April 20, 2023 as the record date for determination of the shareholders entitled to notice of and to vote at the Annual Meeting or any","filed_date":"2023-04-28","accession":"0001654954-23-005412","full_text":"https://origin.rootz.global/static/filing/0001654954-23-005412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"s, or it could impact our ability to successfully commercialize our current product candidates. **Because our ZIVO algae is currently produced by only one grower, the loss of this grower would have a material adverse impact on our operating results and cash flows.** Currently only one facility grows our ZIVO algae. Any termination of a business relationship with, or a significant sustained reduction in business received","filed_date":"2023-03-14","accession":"0001654954-23-002845","full_text":"https://origin.rootz.global/static/filing/0001654954-23-002845.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":28,"context":"ratify the appointment our independent registered public accounting firm for the fiscal year ending December 31, 2022; and | | | | | | | 3. | To approve (on an advisory basis) the compensation of our named executive officers. | | The Board of Directors has fixed the close of business on June 28, 2022 as the record date for determination of the shareholders entitled to notice of and to vote at the Annual Meeting or any a","filed_date":"2022-07-05","accession":"0001654954-22-009260","full_text":"https://origin.rootz.global/static/filing/0001654954-22-009260.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"s, or it could impact our ability to successfully commercialize our current product candidates. **Because our ZIVO algae is currently produced by only one grower, the loss of this grower would have a material adverse impact on our operating results and cash flows.** Currently only one facility grows our ZIVO algae. Any termination of a business relationship with, or a significant sustained reduction in business received","filed_date":"2022-04-22","accession":"0001654954-22-005298","full_text":"https://origin.rootz.global/static/filing/0001654954-22-005298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"idated financial statements include the accounts of Zivo Bioscience, Inc. (Nevada) and its wholly owned subsidiaries, Health Enhancement Corporation (Nevada), HEPI Pharmaceuticals, Inc. (Delaware), WellMetrix, LLC (Delaware), WellMetris, LLC (Delaware), Zivo Bioscience, LLC (Florida), ZIVO Zoologic, Inc. (Delaware), and Zivo Biologic, Inc. (Delaware). All significant intercompany transactions and acc","filed_date":"2022-04-21","accession":"0001654954-22-005221","full_text":"https://origin.rootz.global/static/filing/0001654954-22-005221.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pant holding an Award that constitutes deferred compensation under Section 409A is a specified employee for purposes of Section 409A, no distribution or payment of any amount that is due because of a separation from service (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participants","filed_date":"2022-02-16","accession":"0001654954-22-001759","full_text":"https://origin.rootz.global/static/filing/0001654954-22-001759.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"idated financial statements include the accounts of Zivo Bioscience, Inc. (Nevada) and its wholly owned subsidiaries, Health Enhancement Corporation (Nevada), HEPI Pharmaceuticals, Inc. (Delaware), WellMetrix, LLC (Delaware), WellMetris, LLC (Delaware), Zivo Bioscience, LLC (Florida), ZIVO Zoologic, Inc. (Delaware), and Zivo Biologic, Inc. (Delaware). All significant intercompany transactions and acc","filed_date":"2021-11-15","accession":"0001654954-21-012235","full_text":"https://origin.rootz.global/static/filing/0001654954-21-012235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":41,"context":"pprove the adoption of the Zivo Bioscience, Inc. 2021 Equity Incentive Plan in the form attached as Annex A; and &#xA0; &#xA0;&#xA0;&#xA0; 4. To approve (on an advisory basis) the compensation of our named executive officers. &#xA0; The Board of Directors has fixed the close of business on August 19, 2021 as the record date for determination of the shareholders entitled to notice of and to vote at the Annual Meeting or","filed_date":"2021-09-13","accession":"0001654954-21-010024","full_text":"https://origin.rootz.global/static/filing/0001654954-21-010024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"idated financial statements include the accounts of Zivo Bioscience, Inc. (Nevada) and its wholly-owned subsidiaries, Health Enhancement Corporation (Nevada), HEPI Pharmaceuticals, Inc. (Delaware), WellMetrix, LLC (Delaware), WellMetris, LLC (Delaware), Zivo Bioscience, LLC (Florida), ZIVO Zoologic, Inc. (Delaware), and Zivo Biologic, Inc. (Delaware). All significant intercompany transactions and acc","filed_date":"2021-05-17","accession":"0001078782-21-000455","full_text":"https://origin.rootz.global/static/filing/0001078782-21-000455.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"onal food ingredient and nutritional enhancement for human and animal use. The Company currently has contracts with NutriQuest, Grekin Laboratories, and others for the sale of its algal biomass.  **Wellmetrix** In August 2013, we acquired the assets, consisting primarily of IP rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris","filed_date":"2021-02-25","accession":"0001078782-21-000172","full_text":"https://origin.rootz.global/static/filing/0001078782-21-000172.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"he unaudited condensed consolidated financial statements include the accounts of ZIVO Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., Wellmetrix, LLC (formerly known as WellMetris, LLC), Zivo Bioscience, LLC and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting","filed_date":"2020-11-12","accession":"0001078782-20-000834","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000834.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"he unaudited condensed consolidated financial statements include the accounts of ZIVO Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., Wellmetrix, LLC (formerly known as WellMetris, LLC), and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Compa","filed_date":"2020-08-13","accession":"0001078782-20-000617","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., Wellmetrix, LLC (fka WellMetris, LLC), and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed","filed_date":"2020-05-11","accession":"0001078782-20-000312","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000312.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":41,"context":"ectors, each to serve until the Annual Meeting of shareholders in 2021 and until his or her respective successor is elected and qualified;  2.To approve (on an advisory basis) the compensation of our named executive officers;  3.To approve (on an advisory basis) whether an advisory vote on the compensation of our named executive officers should occur once every one, two or three years; and  4.To consider and act upon su","filed_date":"2020-04-29","accession":"0001078782-20-000294","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000294.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":57,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC as a 100% owned entity of ZIVO. In 2018, we changed the name of WellMetris, LLC to Wellmetrix, LLC (Wellmetrix). We acquired four patent applications as part of the transaction, in addition","filed_date":"2020-03-26","accession":"0001078782-20-000199","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"o fund our normal operations and to fund our research and development initiatives. There is no guarantee that we will receive this funding. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. *We have 1.2 billion shares authorized for issuance.*As of December 31, 2019, we had 394,688,456 shares outstanding. We also had contra","filed_date":"2020-03-26","accession":"0001078782-20-000199","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., Wellmetrix, LLC (fka WellMetris, LLC), and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed","filed_date":"2019-10-28","accession":"0001078782-19-000791","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000791.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetrix, LLC (fka WellMetris, LLC), and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed","filed_date":"2019-08-07","accession":"0001078782-19-000632","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000632.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":47,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC as a 100% owned entity of ZIVO. In 2018, we changed the name of WellMetris, LLC to WellMetrix, LLC (WellMetrix). We acquired four patent applications as part of the transaction, in addition","filed_date":"2019-02-12","accession":"0001078782-19-000119","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"expenses, we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. *We have 700 million shares authorized for issuance.*As of December 31, 2018, we had 180,036,435 shares outstanding. We also had contra","filed_date":"2019-02-12","accession":"0001078782-19-000119","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed consolidated financial","filed_date":"2018-11-14","accession":"0001078782-18-001279","full_text":"https://origin.rootz.global/static/filing/0001078782-18-001279.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed consolidated financial","filed_date":"2018-08-14","accession":"0001078782-18-000852","full_text":"https://origin.rootz.global/static/filing/0001078782-18-000852.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":43,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC (WellMetris) as a 100% owned entity of ZIVO. We acquired four patent applications as part of the transaction, in addition to engineering drawings, prototypes, chemical formulae, validation","filed_date":"2018-02-21","accession":"0001078782-18-000204","full_text":"https://origin.rootz.global/static/filing/0001078782-18-000204.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"expenses, we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. *We only have 700 million shares authorized for issuance.*As of December 31, 2017, we had 141,306,061 shares outstanding. We also had c","filed_date":"2018-02-21","accession":"0001078782-18-000204","full_text":"https://origin.rootz.global/static/filing/0001078782-18-000204.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed consolidated financial","filed_date":"2017-10-19","accession":"0001078782-17-001431","full_text":"https://origin.rootz.global/static/filing/0001078782-17-001431.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":26,"context":"n, as amended (our \"Articles\") to increase the number of authorized shares of common stock from 450,000,000 shares to 700,000,000 shares;  3.To approve (on and advisory basis) the compensation of our named executive officers; and  4.To consider and act upon such other business as may properly come before the Annual Meeting or any adjournment thereof.  The Board of Directors has fixed the close of business on September 2","filed_date":"2017-10-03","accession":"0001078782-17-001338","full_text":"https://origin.rootz.global/static/filing/0001078782-17-001338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed consolidated financial","filed_date":"2017-08-11","accession":"0001078782-17-001087","full_text":"https://origin.rootz.global/static/filing/0001078782-17-001087.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed consolidated financial","filed_date":"2017-05-12","accession":"0001078782-17-000640","full_text":"https://origin.rootz.global/static/filing/0001078782-17-000640.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":33,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC (WellMetris) as a 100% owned entity of ZIVO. We acquired four patent applications as part of the transaction, in addition to engineering drawings, prototypes, chemical formulae, validation","filed_date":"2017-03-31","accession":"0001078782-17-000387","full_text":"https://origin.rootz.global/static/filing/0001078782-17-000387.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"expenses, we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. *We only have 450 million shares authorized for issuance.*As of December 31, 2016, we had 136,745,347 shares outstanding. We also had c","filed_date":"2017-03-31","accession":"0001078782-17-000387","full_text":"https://origin.rootz.global/static/filing/0001078782-17-000387.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"of Consolidation** The consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned Subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys consolidated financial statement","filed_date":"2016-11-14","accession":"0001078782-16-003761","full_text":"https://origin.rootz.global/static/filing/0001078782-16-003761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"n the over the counter market. In the 14 months since our last shareholder meeting, the Company has focused on capital funding activities for the ZIVO algae research and product development for the WellMetris subsidiary. We have had some very recent success I will share with you at the close of this presentation. The funding we did attract over the past year allowed us to keep the algae program movin","filed_date":"2016-11-09","accession":"0001078782-16-003733","full_text":"https://origin.rootz.global/static/filing/0001078782-16-003733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of Consolidation** The consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned Subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed consolidated financial","filed_date":"2016-08-12","accession":"0001078782-16-003231","full_text":"https://origin.rootz.global/static/filing/0001078782-16-003231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC (WellMetris) as a 100% owned entity of ZIVO. We acquired four patent applications as part of the transaction, in addition to engineering drawings, prototypes, chemical formulae, validation","filed_date":"2016-03-29","accession":"0001078782-16-002508","full_text":"https://origin.rootz.global/static/filing/0001078782-16-002508.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":8,"context":"expenses, we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. *We only have 300 million shares authorized for issuance.*As of December 31, 2015, we had 132,156,776 shares outstanding. We also had c","filed_date":"2016-03-29","accession":"0001078782-16-002508","full_text":"https://origin.rootz.global/static/filing/0001078782-16-002508.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of Consolidation** The consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned Subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys consolidated financial statement","filed_date":"2015-11-13","accession":"0001078782-15-001815","full_text":"https://origin.rootz.global/static/filing/0001078782-15-001815.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":29,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC (WellMetris) as a 100% owned entity of ZIVO. We acquired four patent applications as part of the transaction, in addition to engineering drawings, prototypes, chemical formulae, validation","filed_date":"2015-04-06","accession":"0001078782-15-000536","full_text":"https://origin.rootz.global/static/filing/0001078782-15-000536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":7,"context":"expenses, we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. 16 *We only have 200 million shares authorized for issuance.*As of December 31, 2014, we had 128,773,859 shares outstanding. We also ha","filed_date":"2015-04-06","accession":"0001078782-15-000536","full_text":"https://origin.rootz.global/static/filing/0001078782-15-000536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":41,"context":"rove an amendment to our Articles changing the name of our company to Zivo Bioscience, Inc., also included in Appendix A attached hereto;  3. To approve (on an advisory basis) the compensation of our named executive officers; 4. To approve (on an advisory basis) whether an advisory vote on the compensation of our named executive officers should occur once every one, two or three years; and 5. To consider and act upon su","filed_date":"2014-09-05","accession":"0001078782-14-001648","full_text":"https://origin.rootz.global/static/filing/0001078782-14-001648.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":41,"context":"of directors, each to serve until the Annual Meeting of shareholders in 2015 and until his respective successor is elected and qualified;  2. To approve (on an advisory basis) the compensation of our named executive officers; 3. To approve (on an advisory basis) whether an advisory vote on the compensation of our named executive officers should occur once every one, two or three years; and 4. To consider and act upon su","filed_date":"2014-04-30","accession":"0001078782-14-000761","full_text":"https://origin.rootz.global/static/filing/0001078782-14-000761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (Wellness), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC (WellMetris) as a 100% owned entity of HEPI. We assigned all of the intellectual property acquired to WellMetris. The mission of WellMetris is to develop, manufacture, market and sell Welln","filed_date":"2014-03-31","accession":"0001078782-14-000496","full_text":"https://origin.rootz.global/static/filing/0001078782-14-000496.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":7,"context":"expenses, we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds, there will be a material adverse effect on our business, financial condition and results of operations. *Our future success is dependent on our ability to establish strategic partnerships.* We do not have resources to pursue the developmen","filed_date":"2014-03-31","accession":"0001078782-14-000496","full_text":"https://origin.rootz.global/static/filing/0001078782-14-000496.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":96,"match_count":7,"context":"pending material legal proceedings as of February 25, 2021. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Companys business, financial position, results of operations, or cash flows. **Compliance with Environmental Laws** We believe that we are, in all material respects, in compliance with local,","filed_date":"2021-02-25","accession":"0001078782-21-000172","full_text":"https://origin.rootz.global/static/filing/0001078782-21-000172.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZIVO","company":"Zivo Bioscience, Inc.","exchange":"OTC","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"he unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetrix, LLC (fka WellMetris, LLC), and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. **Accounting Estimates** The Companys condensed","filed_date":"2019-05-13","accession":"0001078782-19-000417","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"1a8bec8b0e4ff109744e0330bdee2eb76b0dcab08e503d69d5c9853ba0f21b12","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"21f89187aee345e47aaf7b16b01891a4a95a19ea2d882fcc94858b97b2fe7360","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":68,"hourly_limit":500,"remaining":432,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}